Table 1

Parameters of the experimental groups of mice

db/m–IgG (n = 8)db/m–αT (n = 9)db/db–IgG (n = 8)db/db–αT (n = 9)
Body wt. initial, g20.4  ± 0.3921.2  ± 0.8937.1  ± 0.56*37.0  ± 0.71*
Body wt. final, g23.0  ± 0.3023.8  ± 1.0649.6  ± 0.66*46.3  ± 0.97
Plasma glucose, mg/dl116  ± 798  ± 20430  ± 26*612  ± 16
Urine volume, ml/day0.53  ± 0.130.41  ± 0.134.33  ± 0.56*3.83  ± 0.81*
Kidney wt, mg127  ± 2138  ± 4194  ± 6*176  ± 4*
Kidney wt/body wt, × 10−35.5  ± 0.15.8  ± 0.33.9  ± 0.2*3.7  ± 0.1*
Liver wt, mg1022  ± 391057  ± 652551  ± 75*2269  ± 81*
Plasma TGF-β1, % control100  ± 544  ± 9*134  ± 1449  ± 9*
Plasma creatinine, mg/dl0.34  ± 0.020.38  ± 0.060.62  ± 0.06*0.34  ± 0.04
  • Mice (nondiabetic db/m or diabetic obese db/db) were treated for 8 wk with either control IgG or neutralizing anti-TGF-β antibody (αT). Unless specified, parameters were recorded at the end of the experimental period (16 wk of age). wt., weights. *, P < 0.05 vs. db/m–IgG;  

  • , P < 0.05 vs. db/db–IgG.